MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Global Vision, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Global Vision Selected by Pfizer for Worldwide Deployment of Automated Proofreading Solutions - Docu-Proof, Digital-Page, ScanTVS, BarProof selected by Pfizer to provide end-to-end inspection across their entire packaging workflow - Pfizer.com / GlobalVisionInc.com
Global Vision Selected by Pfizer for Worldwide Deployment of Automated Proofreading Solutions

 

NewswireToday - /newswire/ - Montréal, Québec, Canada, 2013/05/14 - Docu-Proof, Digital-Page, ScanTVS, BarProof selected by Pfizer to provide end-to-end inspection across their entire packaging workflow - Pfizer.com / GlobalVisionInc.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Global Vision, the industry leader in the development of automated proofreading solutions, today announced that it has been selected by Pfizer for worldwide deployment as its proofreading technology solution provider. This deployment enables Pfizer to drive consistency, reduce costs and subjectivity for artwork and labeling verification throughout the entire packaging workflow process.

With a goal to identify, recommend and implement a global harmonized proofreading technology, a project team was formed within Pfizer to evaluate different technologies that could enhance packaging quality. Global Vision’s best-in-class text, artwork, print & barcode technologies were selected by Pfizer to provide complete inspection end-to-end:

• Docu-Proof - text verification and comparison for Regulatory Affairs;
• Digital-Page - artwork & proof revision comparator;
• ScanTVS - print inspection system;
• BarProof - barcode decoder & verification.

“Protecting your brands integrity is the lifeblood of a company’s continued success,” explained Reuben Malz, President of Global Vision. “As a global pharmaceutical leader, Pfizer’s decision to deploy Global Vision’s suite of inspection solutions will help ensure that the high quality control standards, synonymous with Pfizer, are maintained.”

About Global Vision

Global Vision (globalvisioninc.com) is the world leader in the design and delivery of automated proofreading solutions. Its complete suite of advanced solutions featuring text-based, pixel-based and Braille inspection technologies are designed to eliminate printed artwork, text verification, and text comparison related errors, providing end-to-end security at every stage of the workflow process.

Global Vision solutions are widely interoperable and have received commercial endorsement from the world’s leading Pharmaceutical, Consumer Packaged Goods (CPG), and Artwork Management companies.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Global Vision, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Global Vision Selected by Pfizer for Worldwide Deployment of Automated Proofreading Solutions

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Press Office - GlobalVisionInc.com 
514-624-4422 mspooner[.]globalvisioninc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Global Vision, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Global Vision, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan
BASF Launches Hepacor in Switzerland for the Dietary Management of Non-Alcoholic Fatty Liver Disease

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)